ESMO

• Press releases
• Country: United States

Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation

Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab Early antitumor activity also observed in squamous NSCLC, SCLC and prostate cancer SHANGHAI and HANGZHOU, China, Oct. 29,...

• Press releases
• Country: United States

Hengrui presenta investigaciones innovadoras en el Congreso ESMO 2026

-De China al escenario global: Hengrui presenta investigaciones innovadoras en el Congreso ESMO 2026, explorando nuevos enfoques para el tratamiento oncológico Un número récord de 64 presentaciones de investigación pone de relieve la solidez de Hengrui en I+D oncológica y su creciente...

• Press releases
• Country: United States

Median PFS Approaches 14 Months! 3SBio's PD-1/VEGF Bispecific Antibody Posts Impressive Data at ESMO 2026

SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- At the 2026 European Society for Medical Oncology (ESMO) Congress, 3SBio presented long-term follow-up results from a Chinese Phase II clinical study of SSGJ-707 combined with chemotherapy as a first-line treatment for advanced non-small cell lung...

• Press releases
• Country: United States

From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment

Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach SHANGHAI and MADRID, Oct. 28, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's...

• Press releases
• Country: Canada

From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment

Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach MADRID and SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's...

• Country: Cyprus

Natera technology featured in 25 abstracts at ESMO congress

• Country: United States

STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer

• Country: United States

STAT+: Five biotech updates to read after ESMO this weekend

Moderna and Merck are racing to submit their personalized cancer vaccine for FDA approval, expected in 2027, according to Moderna CEO Stéphane Bancel.

• Press releases
• Country: United States

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumors Highlights Three pillars of clinical validation: Clinical data from...

• Press releases
• Country: United States

OncoHost Presents New Research Revealing Biological Drivers of TKI Sensitivity in Metastatic Renal Cell Carcinoma at ESMO 2026

BINYAMINA, Israel and CARY, N.C., Oct. 26, 2026 /PRNewswire/ -- OncoHost, a technology company transforming the approach to predictive precision diagnostics for improved patient outcomes, today announced new research that was presented at the European Society for Medical Oncology (ESMO)...